1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended March 31, 2026, no ne of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
+Added: Other than as set forth as follows, during the three months ended June 30, 2026, none of our directors or Section 16 reporting officers adopted or terminated a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (Rule 10b5-1 Plan) or that constituted a “non-Rule 10b5-1 trading arrangement,” as such term is defined in Item 408(a) of the SEC’s Regulation S-K:
+Added: Rule 10b5-1 Trading Plan
+Added: Aggregate # of
+Added: Securities to be
+Added: Expiration Date
+Added: Purchase/Sale
+Added: Purchased/Sold
+Added: Rule 10b5-1 Plan
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws
−Removed: Settlement and Release Agreement dated March 18, 2026 between the Registrant and GlaxoSmithKline LLC
−Removed: License Agreement dated August 16, 2018 between the Registrant and Emory University
+Added: First Amendment to Loan Agreement dated April 28, 2026 between REGENXBIO RS LLC and affiliate of Healthcare Royalty Management, LLC
Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002
1 unchanged sentence
Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C.
−Removed: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets
3 unchanged sentences
(v) Notes to Consolidated Financial Statements
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101)
−Removed: Portions of this exhibit have been omitted.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 formatted in Inline XBRL (included in Exhibit 101)
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc.
2 unchanged sentences
REGENXBIO Inc.
+Added: August 6, 2026
/s/ Curran Simpson
2 unchanged sentences
(Principal Executive Officer)
+Added: August 6, 2026
/s/ Mitchell Chan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.